Related Experiment Video
Updated: May 20, 2026

07:17
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
Atypical angioimmunoblastic T-cell lymphomas masquerading as systemic polyclonal B-immunoblastic proliferation.
Bhavesh Papadi1, Jacek M Polski, David R Clarkson
1Department of Pathology, University of South Alabama, Mobile, AL 36617, USA.
Virchows Archiv : an International Journal of Pathology
|July 14, 2012
Summary
Angioimmunoblastic T cell lymphoma (AITL) can mimic other conditions, presenting a diagnostic challenge. Early screening of similar cases is crucial for accurate AITL diagnosis.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Angioimmunoblastic T cell lymphoma (AITL) is a rare peripheral T cell lymphoma originating from follicular T helper cells.
- AITL presents with diverse clinical and morphological features, often challenging diagnosis.
- Neoplastic cells in AITL can be obscured by reactive polyclonal B immunoblasts and plasma cells.
Observation:
- AITL-associated B cell and plasma cell proliferation results from cytokine dysregulation, notably interleukin-6, by neoplastic T cells.
- Systemic polyclonal B immunoblast and plasma cell proliferation characterizes SPBIP, a condition with unknown etiology.
- Two AITL cases exhibited atypical features resembling SPBIP, complicating initial diagnosis.
Findings:
- The reported AITL cases demonstrated unusual presentations that mimicked SPBIP.
- Diagnostic difficulty arose from the complex cellular infiltrates in these AITL cases.
- The study underscores the overlap in presentation between AITL and SPBIP-like conditions.
Implications:
- These findings emphasize the necessity of considering AITL in the differential diagnosis of polyclonal plasmacytosis and SPBIP.
- Screening patients with SPBIP-like presentations for underlying AITL is recommended.
- Improved diagnostic strategies are needed for challenging AITL cases with atypical features.
Related Concept Videos
Cells of the Adaptive Immune Response
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Special Features of Adaptive Immunity
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Cell-mediated Immune Responses
Overview
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
